Navigation Links
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
Date:5/16/2013

inflammatory cytokines such as interleukin 6 (IL-6).  Its selective JAK1 inhibition profile avoids inhibition of JAK2 which offers a unique advantage in Crohn's disease.  Inhibition of JAK2 has shown anemia and reduced formation of blood cells in clinical studies with other JAK inhibitors, which is a particular concern in patients with inflammatory bowel disease, as blood loss through gastrointestinal bleeding often already causes anemia in these patients.  Therefore, GLPG0634 may potentially support a better safety profile than other JAK inhibitors.

"AbbVie supports the start of this innovative study in Crohn's disease with GLPG0634.  Our experience within gastroenterology, combined with a novel alternative treatment for this disease may provide a greater benefit to patients in the future," said Scott Brun , M.D., vice president, pharmaceutical development, AbbVie.

"Galapagos and AbbVie are moving forward with GLPG0634, expanding the scope of the development program into inflammatory bowel disease.  The innovative Phase 2 program in Crohn's disease is designed to move rapidly into Phase 3 when successful," said Onno van de Stolpe , CEO of Galapagos.  "Galapagos is in a strong financial position to fund the Crohn's program, in addition to the Phase 2b program with GLPG0634 in RA and our other proprietary clinical and pre-clinical programs.  Our pipeline continues to mature in stage and scope, now that we have three Phase 2 molecules in five inflammatory indications, all with readouts by mid 2015 or earlier."

About candidate drug GLPG0634
GLPG0634 is an orally-available, novel Janus kinase (JAK) inhibitor with selectivity for JAK1 developed by Galapagos.  JAKs are critical components of signalling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in rheumatoid arthritis patients.  JAK inhib
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
2. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
3. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
4. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
5. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie to Host First-Quarter Earnings Conference Call
8. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
9. AbbVie to Present at Barclays Global Health Care Conference
10. AbbVie Issues Inaugural Full-Year Outlook for 2013
11. AbbVie Named to S&P 500 Dividend Aristocrat Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ) ... ended June 28, 2014. Third Quarter Financial ... to $632.6 million, reflecting operational growth of 0.5% and ... same period in the prior year. , Revenues ... Breast Health revenues grew 3.5%. , GYN Surgical ...
(Date:7/30/2014)... 2014  Cepheid (Nasdaq: CPHD ) ... Premier will end on September 30, 2014.  Customers ... able to continue their relationship with Cepheid through ... and ROi, in addition to the recently announced ... "Cepheid has always recognized and supported the ...
(Date:7/30/2014)... CryoLife, Inc. (NYSE: CRY), a leading medical device and ... announced today that its Board of Directors has approved ... of $0.03 per share of common stock outstanding.  The ... paid on September 19, 2014 to all common stockholders ... date for the quarterly dividend is September 10, 2014.  ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3
... AuraSense Therapeutics, a biopharmaceutical company commercializing spherical ... and chemo-therapeutics for a variety of diseases, ... for cardiovascular disorders, has closed its Series ... a subsidiary of Abbott.  Other key individual ...
... 2011 /PRNewswire-Asia/ -- The Ministry of Health and ... Industry Development Institute (President Ko Kyung-hwa) launched a ... foreign patients by designating 38 tasks, including seven ... for medical injuries and granting permission for drug ...
Cached Medicine Technology:AuraSense Therapeutics Secures Series B Equity Investment 2Medical Korea's Medical Policy Improvement Project for Foreign Patients 2
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... New York (PRWEB) July 30, 2014 ... uncontrollable brain bleeding has filed a Xarelto lawsuit ( ... the blood thinner, Bernstein Liebhard LLP reports. According to ... for the District of Vermont on July 25th, the ... when he suffered an irreversible brain bleed that ultimately ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2
... just received a major grant from the National Center ... the National Institutes of Health (NIH) and lead Federal ... new grant creates a Center of Excellence for Research ... will focus on Alzheimers disease. The new Center has ...
... 2007. A report to be published in an upcoming ... for urgent attention to the politically sensitive issue of border ... in the face of a catastrophic flu pandemic . ... of a strain of avian influenza A (HN51) in Northern ...
... today,announced it received a $250,000 grant from the ... support services. The university will use the ... professions. The newly created program, named the ... help the university recruit and support,Hispanic women in ...
... for Eating Disorders Reports Eating Disorders Develop or ... Worsen Upon Returning ... Eating Disorders, http://www.remudaranch.com, the nation,s leading eating disorder treatment,center, ... A majority of eating disorders begin at ages 14 and ...
... Governor,Arnold Schwarzenegger held a press conference announcing ... state legislature aimed at producing,reforms to California,s ... Policies Institute issued the following statement:, ... solve California,s,health care crisis," said Jill Jenkins, ...
... YORK, Oct. 10 Philip K. Howard, Chair of Common,Good, ... in response to a recent study on health courts that ... "The American Association of Justice (formerly known as the Association ... a study that it commissioned on the ...
Cached Medicine News:Health News:Mount Sinai recognized as Center of Excellence for Research in Alzheimer's disease 2Health News:Report highlights inadequate pandemic planning as a threat to EU security 2Health News:Wal-Mart Foundation Provides Brenau University $250,000 Health Care scholarships Grant for Hispanic Women 2Health News:Wal-Mart Foundation Provides Brenau University $250,000 Health Care scholarships Grant for Hispanic Women 3Health News:Going Back to School Can Trigger Eating Disorders 2Health News:Going Back to School Can Trigger Eating Disorders 3Health News:Common Good Responds to a Trial Bar Study Opposing Health Courts 2
Kinetic and endpoint methods for the quantitative determination of creatinine in serum....
Intended for the quantitative determination of creatinine in serum, plasma, or urine. Reaction: Endpoint. Wavelength: 340 nm. Linearity: 10 mg/dL (880 mol/L). Two vials, dry powder reagents....
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
Medicine Products: